Macias Alba T, Mia Md Younus, Xia Guanjun, Hayashi Jun, MacKerell Alexander D
Department of Pharmaceutical Sciences, University of Maryland, 20 Penn Street, Baltimore, Maryland 21201, USA.
J Chem Inf Model. 2005 Nov-Dec;45(6):1759-66. doi: 10.1021/ci050225z.
Compound selection based on chemical similarity has been used to validate active "parent" compounds identified via database searching as viable lead compounds and to obtain initial structure-activity relationships for those leads. Twelve parent compounds that have inhibitory activity against the SH2 domain of the p56 T-cell tyrosine kinase (Lck) are the focus of this study. Lck is involved in the T-cell mediated immune response, and inhibitors of Lck protein-protein interactions could potentially be used to develop novel immunosuppressants. Similarity searches for each parent compound were performed using 2D structural fingerprints on a database containing 1,300,000 commercially available compounds. The inhibitory activity of the selected compounds was assessed using enzyme immunoassay (EIA). In general, the most active parent compounds yield the most high activity similar compounds; however, in two cases low activity parent compounds (i.e. inhibitory activity < 25% at 100 microM) yielded multiple similar compounds with activities > 60%. Such compounds may, therefore, be considered as viable lead compounds for optimization. Structure-activity relationships were explored by examining both ligand structures and their computed bound conformations to the protein. Functional groups common to the active compounds as well as key amino acid residues that form hydrogen bonds with the active compounds were identified. This information will act as the basis for the rational optimization of the lead compounds.
基于化学相似性的化合物筛选已被用于验证通过数据库搜索确定的具有活性的“母体”化合物作为可行的先导化合物,并获得这些先导化合物的初始构效关系。本研究聚焦于12种对p56 T细胞酪氨酸激酶(Lck)的SH2结构域具有抑制活性的母体化合物。Lck参与T细胞介导的免疫反应,Lck蛋白-蛋白相互作用的抑制剂有可能被用于开发新型免疫抑制剂。使用二维结构指纹图谱在一个包含130万种市售化合物的数据库中对每种母体化合物进行相似性搜索。使用酶免疫测定(EIA)评估所选化合物的抑制活性。一般来说,活性最高的母体化合物会产生最多的高活性相似化合物;然而,在两个案例中,低活性母体化合物(即在100 microM时抑制活性<25%)产生了多种活性>60%的相似化合物。因此,这类化合物可被视为优化的可行先导化合物。通过检查配体结构及其与蛋白质计算得出的结合构象来探索构效关系。确定了活性化合物共有的官能团以及与活性化合物形成氢键的关键氨基酸残基。这些信息将作为先导化合物合理优化的基础。